8
Participants
Start Date
April 27, 2022
Primary Completion Date
September 7, 2022
Study Completion Date
September 7, 2022
ST266
Topical ocular application: one drop four times a day for eight weeks
0.67% Sodium Chloride Ophthalmic Solution
Topical ocular application: one drop four times a day for eight weeks
Open-label ST266
Open label extension for non-healers after completion of double-blind treatment phase: topical ocular application of one drop four times a day for eight weeks
Ophthalmic Partners, PC, Bala-Cynwyd
University of Maryland Eye Associates, Baltimore
WVU Eye Institute, Morgantown
UNC Kittner Eye Center, Chapel Hill
Bowden Eye & Associates, Jacksonville
Millennium Clinical Research, Inc, Miami
MedEye Associates, Miami
Shettle Eye Research, Largo
Piedmont Eye Center, Lynchburg
Trinity Research Group, Dothan
Vanderbilt Eye Institute, Nashville
Cincinnati Eye Institute, Edgewood
OSU Wexner Medical Center, Columbus
Cincinnati Eye Institute, Cincinnati
The Eye Centers of Racine and Kenosha, Kenosha
University of Wisconsin, Madison
Mercy Clinic Eye Specialists- Ophthalmology, Springfield
UNMC Truhlsen Eye Institute, Omaha
University of Arkansas for Medical Sciences, Little Rock
Texas Eye Research Center, Hurst
Houston Eye Associates, Houston
Baylor College of Medicine, Houston
Blanton Eye Institute/Houston Methodist Eye Associates, Houston
R and R Eye Research, LLC, San Antonio
UCLA Stein Eye Institute, Los Angeles
UCLA Doheny Eye Center, Pasadena
California Eye Specialists Medical Group, Pasadena
Atlantis Eye Care, Huntington Beach
Stanford, Palo Alto
Tufts Medical Center, Boston
Massachusetts Eye and Ear, Boston
Lead Sponsor
Collaborators (1)
IQVIA Biotech
INDUSTRY
Noveome Biotherapeutics, formerly Stemnion
INDUSTRY